|
 Under terms of the deal, BeiGene will earn $650 million in an
upfront cash payment from Novartis, and up to $1.55 billion in
milestone payments and royalties on product sales, the
Beijing-headquartered company said in a statement.
Novartis will co-develop and commercialize tislelizumab in North
America, the European Union, Japan and six other countries, BeiGene
said, adding BeiGene would be responsible for funding ongoing
clinical trials of tislelizumab.
[to top of second column] |
 Both parties have freedom to
conduct combination trials globally under the
deal, it said.
Chinese regulators last June accepted Hong
Kong-listed BeiGene's new drug application of
tislelizumab combining with chemotherapy for
treatment of patients with advanced non-squamous
non-small cell lung cancer.
(Reporting by Derek Francis in Bengaluru;
editing by Richard Pullin)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
